Healthcare / Drug Manufacturers - Specialty & GenericKSE
$1384.00
-38.00 (-2.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-8.2B · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47.0B
P/E
24.3x
↑EV/EBITDA
11.9x
↓ROE
1.9%
↑Gross Margin
54.8%
↑Debt/Equity
1.00
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.7%
FCF CAGR
—
FCF margin
-4.4%
FCF / Net income
-4.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $195.25B · net income $1.90B · FCF $-8.54B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $195.25B | $195.25B | $186.44B | $169.57B | $152.13B |
| Net Income | $1.90B | $1.90B | $-3.03B | $-4.52B | $7.87B |
| EBITDA | $11.70B | $11.70B | $5.67B | $4.52B | $10.63B |
| EPS | 57.00 | 57.00 | -91.00 | -134.00 | 233.00 |
| Gross Margin | 54.8% | 54.8% | 56.3% | 56.2% | 51.3% |
| Operating Margin | 3.5% | 3.5% | 1.0% | 0.6% | 4.2% |
| Net Margin | 1.0% | 1.0% | -1.6% | -2.7% | 5.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.00 | 1.00 | 0.90 | 1.08 | 0.93 |
| Current Ratio | 0.95 | 0.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.54B | $-8.54B | $-2.74B | $-8.17B | $3.53B |
| Returns | |||||
| ROE | 1.9% | 1.9% | -3.1% | -5.4% | 8.8% |
| Valuation | |||||
| P/E | 24.28 | 24.28 | — | — | 12.73 |
| EV/EBITDA | 11.87 | 11.87 | 25.53 | 35.86 | 16.79 |
| P/B | 0.47 | 0.47 | 0.64 | 0.95 | 1.12 |
| Growth & Yield | |||||
| Revenue Growth | 4.7% | 4.7% | 10.0% | 11.5% | — |
| EPS Growth | 162.6% | 162.6% | 32.1% | -157.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.2%
EPS terminal req.
$122.81
Spread vs growth
133.5%
5Y implied EPS CAGR
21.1%
EPS terminal req.
$148.60
Spread vs growth
141.5%
10Y implied EPS CAGR
15.4%
EPS terminal req.
$239.32
Spread vs growth
147.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-91.00 → 57.00
Residual
-15.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.